Interferon-β-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis

Journal of Neurology

Volumn 250, Issue 10, 2003, Pages 1224-1228

  Yushchenko, Maryna ^a   Mäder, Michael ^a   Elitok, Ercan ^a   Bitsch, Andreas ^b   Dressel, Alexander ^c   Tumani, Hayrettin ^d   Bogumil, Timon ^e   Kitze, Bernd ^a   Poser, Sigrid ^a   Weber, Frank ^f  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b Ruppiner Kliniken GmbH   (Germany)

^c UNIVERSITY OF GREIFSWALD   (Germany)

^d UNIVERSITY OF ULM   (Germany)

^e BAYER PHARMA AG   (Germany)

^f MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

Interferon ; Matrix metalloproteinase; Multiple sclerosis primary chronic progressive; Therapy; Tissue inhibitor of matrix metalloproteinase

Indexed keywords

GELATINASE B; INTERFERON BETA SERINE; RECOMBINANT CYTOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; LYMPHOCYTE MIGRATION; MALE; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE; ZYMOGRAPHY;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERFERON-BETA; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; MULTIPLE SCLEROSIS;

EID: 0142074749     PISSN: 03405354     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00415-003-0191-4     Document Type: Article

References (22)

1. Beck J, Rondot P, Catinot L, Falcoff E, Kirchner H, Wietzerbin J (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: do cytokines trigger off exacerbations? Acta Neurol Scand 78: 318-323
2. Beuche W, Yushchenko M, Mäder M, Maliszewska M, Felgenhauer K, Weber F (2000) Matrix metalloproteinase-9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 11:3419-3422
3. Chandler S, Miller KM, Clements JM, Lury J, Corkill D, Anthony DC, Adams SE, Gearing AJ (1997) Matrix metalloproteinases, tumor necrosis factor and multiple sclerosis: an overview. J Neuroimmunol 72:155-161
4. Dubois B, Leary S, Nelissen I, Opdenakker G, Thompson A, Giovannoni G (2001) Serum MMP-9 in primary progressive multiple sclerosis patients treated with interferon beta-1a. Mult Scler 7:S104-S104
5. Durelli L, Verdun E, Barbero P, Bergui M, Versino E, Ghezzi A, Montanari E, Zaffaroni M (2002) Every-other-day interferon beta-1b versus once-weekly interferon beta-1 a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN). Lancet 359:1453-1460
6. Galboiz Y, Shapiro S, Lahat N, Rawashdeh H, Miller A (2001) Matrix metalloproteinases and their tissue inhibitors as markers of disease subtype and response to interferon-beta therapy in relapsing and secondary-progressive multiple sclerosis patients. Ann Neurol 50:443-451
7. Goodin DS, Frohman EM, Garmany GP Jr, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, Van den Noort S (2002) Disease modifying therapies in multiple sclerosis: Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurol 58:169-178
8. Hartung HP, Kieseier BC (2000) The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system. J Neuroimmunol 107:140-147
9. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K (1999) Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study. Brain 122: 191-197
10. Lichtinghagen R, Seifert T, Kracke A, Marckmann S, Wurster U, Heidenreich F (1999) Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis. J Neuroimmunol 99:19-26
11. Lindberg RL, De Groot CJ, Montagne L, Freitag P, van d, V, Kappos L, Leppert D (2001) The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain 124: 1743-1753
12. Maliszewska M, Mäder M, Schöll U, Hardeland R, Felgenhauer K, Beuche W, Weber F (2001) Development of an ultra sensitive enzyme immuno assay for the determination of matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid. J Neuroimmunol 116:233-237
13. McDonnell GV, Hawkins SA (1997) Application of the Poser criteria in primary progressive multiple sclerosis. Ann Neurol 42:982-983
14. Montalban X, Brieva L, Tintore M, Borras C, Rio J, Nos C, Aymerich X, Alonso J, Horno J, Vicente M, Rovira A (2002) Single center, dbpc, randomised trial of interferon beta 1b in primary progressive and transitional progressive multiple sclerosis: an exploratory phase II study. Mult Scler 8:S62-S62
15. Newman TA, Woolley ST, Hughes PM, Sibson NR, Anthony DC, Perry VH (2001) T-cell- and macrophage-mediated axon damage in the absence of a CNS-specific immune response: involvement of metalloproteinases. Brain 124:2203-2214
16. Ozenci V, Kouwenhoven M, Teleshova N, Pashenkov M, Fredrikson S, Link H (2000) Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta. J Neuroimmunol 108:236-243
17. Rieckmann P, Albrecht M, Kitze B, Weber T, Tumani H, Broocks A, Lüer W, Helwig A, Poser S (1995) Tumor necrosis factor-α messenger RNA expression in patients with relapsing-remitting multiple sclerosis is associated with disease activity. Ann Neurol 37: 82-88
18. Thompson AJ, Polman CH, Miller DH, McDonald WI, Brochet B, Filippi MM, X, De Sa J (1997) Primary progressive multiple sclerosis. Brain 120: 1085-1096
19. Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P (1999) Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1 b treatment in relapsing-remitting MS. Neurology 53: 1402-1408
20. Waubant E, Gee L, Miller K, Stabler G, Goodkin D (2001) IFN-beta1 a may increase serum levels of TIMP-1 in patients with relapsing-remitting multiple sclerosis. J Interferon Cytokine Res 21:181-185
21. Waubant E, Goodkin D, Bostrom A, Bacchetti P, Hietpas J, Lindberg R, Leppert D (2003) IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMSNeurology 60:52-57
22. Waubant E, Goodkin DE, Gee L, Bacchetti P, Sloan R, Stewart T, Andersson PB, Stabler G, Miller K (1999) Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis.Neurology 53:1397-1401